"If a company isn't IPO-ready, it better be M&A-ready," says Nanna Lüneborg of Forbion. She and co-founder Sander Slootweg sit down with Bloomberg Intelligence analyst Sam Fazeli to explain Forbion’s blueprint for success in Europe’s maturing biotech ecosystem. From incubating CNS-focused gene therapy startups to executing €100M+ financing rounds, Forbion’s thesis is rooted in scientific rigor and commercially sound exits. They also share how Europe’s capital scarcity offers hidden advantages—and why late-stage buyers still pay up for must-have innovation.

<p>"If a company isn't IPO-ready, it better be M&amp;A-ready," says Nanna L&uuml;neborg of Forbion. She and co-founder Sander Slootweg sit down with Bloomberg Intelligence analyst Sam Fazeli to explain Forbion&rsquo;s blueprint for success in Europe&rsquo;s maturing biotech ecosystem. From incubating CNS-focused gene therapy startups to executing &euro;100M+ financing rounds, Forbion&rsquo;s thesis is rooted in scientific rigor and commercially sound exits. They also share how Europe&rsquo;s capital scarcity offers hidden advantages&mdash;and why late-stage buyers still pay up for must-have innovation.</p>

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

<p>Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.</p>

Vanguards of Health Care by Bloomberg Intelligence

Inside Forbion’s M&A-First Playbook for Building Europe’s Biotech Winners

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d7ec843c-3f29-48f7-9328-b30f00c5fdca/transcript

Advertisement